Clinical and health outcomes initiative in comparative effectiveness for bipolar disorder (Bipolar CHOICE): A pragmatic trial of complex treatment for a complex disorder

Clinical Trials

Volumn 11, Issue 1, 2014, Pages 114-127

  Nierenberg, Andrew A ^a   Sylvia, Louisa G ^a   Leon, Andrew C ^b   Reilly Harrington, Noreen A ^a   Shesler, Leah W ^a   McElroy, Susan L ^c   Friedman, Edward S ^d   Thase, Michael E ^e   Shelton, Richard C ^f   Bowden, Charles L ^g   Tohen, Mauricio ^g   Singh, Vivek ^g   Deckersbach, Thilo ^a   Ketter, Terence A ^h   Kocsis, James H ^b   McInnis, Melvin G ⁱ   Schoenfeld, David ^a   Bobo, William V ^j,k   Calabrese, Joseph R ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c LINDNER CENTER OF HOPE   (United States)

^d UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

^f UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^g UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^h STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^j VANDERBILT UNIVERSITY   (United States)

^k CASE WESTERN RESERVE UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; CLINICAL PROTOCOLS; COMPARATIVE EFFECTIVENESS RESEARCH; DIBENZOTHIAZEPINES; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTENTION TO TREAT ANALYSIS; LITHIUM; MALE; MIDDLE AGED; PATIENT SELECTION; PROSPECTIVE STUDIES; RESEARCH DESIGN; SINGLE-BLIND METHOD; TREATMENT OUTCOME;

EID: 84893942236     PISSN: 17407745     EISSN: 17407753     Source Type: Journal    
DOI: 10.1177/1740774513512184     Document Type: Article

References (60)

1. Diagnostic and Statistical Manual of Mental Disorders, (DSM-IV). 4 th edn). American Psychiatric Association Press, Inc., Washington, DC, 1994. Washington, DC: American Psychiatric Association Press, Inc ; 1994 :
2. Kessler RC, Chiu WT, Demler O, Walters EE. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005 ; 62: 617-27
3. Merikangas KR, Akiskal HS, Angst J, et al. Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2007 ; 64: 543-52
4. Osby U, Brandt L, Correia N, Ekbom A, Sparen P. Excess mortality in bipolar and unipolar disorder in Sweden. Arch Gen Psychiatry. 2001 ; 58: 844-50
5. Roshanaei-Moghaddam B, Katon W. Premature mortality from general medical illnesses among persons with bipolar disorder: A review. Psychiatr Serv. 2009 ; 60: 147-56
6. Nierenberg AA, Gray SM, Grandin LD. Mood disorders and suicide. J Clin Psychiatry. 2001 ; 62: 27-30
7. Nock MK, Hwang I, Sampson NA, Kessler RC. Mental disorders, comorbidity and suicidal behavior: Results from the National Comorbidity Survey Replication. Mol Psychiatry. 2010 ; 15: 868-76
8. Murray CJL, Lopez AD. Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet. 1997 ; 349: 1436-42
9. Dilsaver SC. An estimate of the minimum economic burden of bipolar I and II disorders in the United States: 2009. J Affect Disord. 2011 ; 129: 79-83
10. Ray WA, Meredith S, Thapa PB, et al. Antipsychotics and the risk of sudden cardiac death. Arch Gen Psychiatry. 2001 ; 58: 1161-67
11. Feighner JP, Jacobs RS, Jackson RE, et al. A double-blind comparative trial with mianserin and amitriptyline in outpatients with major depressive disorders. Br J Clin Pharmacol. 1983 ; 15: 227S - 37S
12. Kannel WB, Dawber TR, Kagan A, Revotskie N, Stokes J. Factors of risk in the development of coronary heart disease - six-year follow-up experience. The Framingham Study. Ann Intern Med. 1961 ; 55 (1). 33-50
13. Gao K, Calabrese JR. Impact of excluding comorbid anxiety and substance abuse/dependence on generalizability of clinical trials in bipolar disorder. 48th Annual NCDEU Meeting ; Phoenix, AZ ;. 121.
14. Tinetti ME, Studenski SA. Comparative effectiveness research and patients with multiple chronic conditions. N Engl J Med. 2011 ; 364: 2478-81
15. Young AH, McElroy SL, Bauer M, et al. Double-blind, placebo-controlled study with acute phase of quetiapine in adults with acute and continuation treatment with quetiapine in adults with bipolar depression (EMBOLDEN I). J Clin Psychiatry. 2010 ; 71: 150-62
16. McElroy SL, Weisler RH, Chang W, et al. A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II). J Clin Psychiatry. 2010 ; 71: 163-74
17. Calabrese JR, Keck PE, Macfadden W, et al. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry. 2005 ; 162: 1351-60
18. Thase ME, Macfadden W, Weisler RH, et al. Efficacy of quetiapine monotherapy in bipolar I and II depression: A double-blind, placebo-controlled study (the BOLDER II study). J Clin Psychopharmacol. 2006 ; 26: 600-09
19. Suppes T, Vieta E, Liu S, Brecher M, Paulsson B. Maintenance treatment for patients with bipolar I disorder: Results from a North American study of quetiapine in combination with lithium or divalproex (trial 127). Am J Psychiatry. 2009 ; 166: 476-88
20. Ray WA, Chung CP, Murray KT, Hall K, Stein CM. Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med. 2009 ; 360: 225-35
21. Yatham LN, Kennedy SH, Schaffer A, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: Update 2009. Bipolar Disord. 2009 ; 11: 225-55
22. Bauer M, Bschor T, Pfennig A, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders in primary care. World J Biol Psychiatry. 2007 ; 8: 67-104
23. Grunze H, Vieta E, Goodwin GM, et al. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: Update 2009 on the treatment of acute mania. World J Biol Psychiatry. 2009 ; 10: 85-116
24. Grof P, Muller-Oerlinghausen B. A critical appraisal of lithium's efficacy and effectiveness: The last 60 years. Bipolar Disord. 2009 ; 11: 10-19
25. Baldessarini RJ. Treatment research in bipolar disorder: Issues and recommendations. CNS Drugs. 2002 ; 16: 721-29
26. Baldessarini RJ, Tondo L, Davis P, et al. Decreased risk of suicides and attempts during long-term lithium treatment: A meta-analytic review. Bipolar Disord. 2006 ; 8: 625-39
27. Angst J, Angst F, Gerber-Werder R, Gamma A. Suicide in 406 mood-disorder patients with and without long-term medication: A 40 to 44 years' follow-up. Arch Suicide Res. 2005 ; 9: 279-300
28. Goodwin FK, Fireman B, Simon GE, et al. Suicide risk in bipolar disorder during treatment with lithium and divalproex. JAMA. 2003 ; 290: 1467-73
29. Angst F, Stassen HH, Clayton PJ, Angst J. Mortality of patients with mood disorders: Follow-up over 34-38 years. J Affect Disord. 2002 ; 68: 167-81
30. Malhi GS, Tanious M, Das P, Berk M. The science and practice of lithium therapy. Aust N Z J Psychiatry. 2012 ; 46: 192-211
31. Baldessarini RJ, Vieta E, Calabrese J, Tohen M, Bowden CL. Bipolar depression: Overview and commentary. Harv Rev Psychiatry. 2010 ; 18: 143-57
32. Judd LL, Akiskal HS, Schettler PJ, et al. A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder. Arch Gen Psychiatry. 2003 ; 60: 261-69
33. Judd LL, Akiskal HS, Schettler PJ, et al. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry. 2002 ; 59: 530-37
34. Bowden CL. Anticonvulsants in bipolar disorders: Current research and practice and future directions. Bipolar Disord. 2009 ; 11: 20-33
35. Smith LA, Cornelius VR, Azorin JM, et al. Valproate for the treatment of acute bipolar depression: Systematic review and meta-analysis. J Affect Disord. 2009 ; 122: 1-9
36. Muzina DJ, Gao K, Kemp DE, et al. Acute efficacy of divalproex sodium versus placebo in mood stabilizer naïve bipolar I or II depression. J Clin Psychiatry. 2011 ; 72: 813-19
37. Calabrese JR, Bowden CL, Sachs GS, et al. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. J Clin Psychiatry. 1999 ; 60: 79-88
38. Calabrese JR, Huffman RF, White RL, et al. Lamotrigine in the acute treatment of bipolar depression: Results of five double-blind, placebo-controlled clinical trials. Bipolar Disord. 2008 ; 10: 323-33
39. Van der Loos ML, Mulder PG, Hartong EG, et al. Efficacy and safety of lamotrigine as add-on treatment to lithium in bipolar depression: A multicenter, double-blind, placebo-controlled trial. J Clin Psychiatry. 2009 ; 70: 223-31
40. Geddes JR, Goodwin GM, Rendell J, et al. Lithium plus valproate combination therapy versus monotherapy for relapse prevention in bipolar I disorder (BALANCE): A randomised open-label trial. Lancet. 2010 ; 375: 385-95
41. Merikangas KR, Jin R, He JP, et al. Prevalence and correlates of bipolar spectrum disorder in the world mental health survey initiative. Arch Gen Psychiatry. 2011 ; 68: 241-51
42. Baldessarini R, Henk H, Sklar A, Chang J, Leahy L. Psychotropic medications for patients with bipolar disorder in the United States: Polytherapy and adherence. Psychiatr Serv. 2008 ; 59: 1175-83
43. Centorrino F, Ventriglio A, Vincenti A, Talamo A, Baldessarini RJ. Changes in medication practices for hospitalized psychiatric patients: 2009 versus 2004. Hum Psychopharmacol. 2010 ; 25: 179-86
44. Suppes T, Dennehy EB, Hirschfeld RMA, et al. The Texas implementation of medication algorithms: Update to the algorithms for treatment of bipolar I disorder. J Clin Psychiatry. 2005 ; 66: 870-86
45. Nierenberg AN, Sylvia LG, Leon A, et al. Lithium Treatment - Moderate Dose Use Study (LiTMUS): Rationale and design. Clin Trials. 2009 ; 6: 637-48
46. Kupfer DJ. The increasing medical burden in bipolar disorder. JAMA. 2005 ; 293: 2528-30
47. Guy W ECDEU Assessment Manuel for Psychopharmacology. Washington, DC: U.S. Government Printing Office ; 1976 :
48. Kagan A, Dawber TR, Kannel WB, Revotskie N. The Framingham study: A prospective study of coronary heart disease. Fed Proc. 1962 ; 21: 52-57
49. Meyer JM, Koro CE. The effects of antipsychotic therapy on serum lipids: A comprehensive review. Schizophr Res. 2004 ; 70: 1-17
50. Third report of the expert panel on detection, evaluation and treatment of high blood cholesterol in adults (ATP III). Bethesda, MD: National Institutes of Health ; 2002 :
51. Leon AC, Solomon DA, Mueller TI, et al. A brief assessment of psychological functioning of subjects with bipolar I disorder: The LIFE-RIFT. Longitudinal Interval Follow-up Evaluation-Range Impaired Functioning Tool. J Nerv Ment Dis. 2000 ; 188: 805-12
52. Bowden CL, Singh V, Thompson P, et al. Development of the bipolar inventory of symptoms scale. Acta Psychiatr Scand. 2007 ; 116: 189-94
53. Gonzalez JM, Bowden CL, Katz MM, et al. Development of the Bipolar Inventory of Symptoms Scale: Concurrent validity, discriminant validity and retest reliability. Int J Methods Psychiatr Res. 2008 ; 17: 198-209
54. Thompson PM, Gonzalez JM, Singh V, et al. Principal domains of behavioral psychopathology identified by the Bipolar Inventory of Signs and Symptoms Scale (BISS). Psychiatry Res. 2010 ; 175: 221-26
55. Leon AC, Demirtas H, Hedeker D. Bias reduction with an adjustment for participants' intent to dropout of a randomized controlled clinical trial. Clin Trials. 2007 ; 4: 540-47
56. Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): The development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998 ; 59: 22-33
57. ICH Harmonised Tripartite Guideline. Statistical principles for clinical trials. Stat Med. 1999 ; 18: 1905-42
58. Leon AC. Sample-size requirements for comparisons of two groups on repeated observations of a binary outcome. Eval Health Prof. 2004 ; 27: 34-44
59. Suppes T, Rush AJJ, Kraemer HC, Webb A. Treatment algorithm use to optimize management of symptomatic patients with a history of mania. J Clin Psychiatry. 1998 ; 59: 89-96
60. Hirschfeld RM, Lewis L, Vornik LA. Perceptions and impact of bipolar disorder: How far have we really come? Results of the national depressive and manic-depressive association 2000 survey of individuals with bipolar disorder. J Clin Psychiatry. 2003 ; 64: 161-74